Gynecologic Cancers

HPV Vaccination May Offer Protection Against Cervical Precancer

By May 11, 2018

The authors concluded, "There is high-certainty evidence that HPV vaccines protect against cervical precancer in adolescent girls and young women aged 15 to 26," while also indicated that future studies should have long-term follow-up.

Long-Term Cardiovascular Risk for Endometrial Cancer Survivors

May 08, 2018

The researchers found that there were increased cardiovascular risks among endometrial cancer survivors for phlebitis, thrombophlebitis, and thromboembolism (hazard ratio, 2.07); pulmonary heart disease (hazard ratio, 1.74); and atrial fibrillation (hazard ratio, 1.5).

Mortality Risk Persists for Cancer Tied to Prenatal DES Exposure

May 04, 2018

Women with DES-related clear-cell adenocarcinoma had 27-fold higher mortality at 10 to 34 years

New Drug Combo Ups Survival in HER2/neu Uterine Serous Cancer

April 18, 2018

Among 41 patients with stage III or IV disease undergoing primary treatment, the median progression-free survival was 9.3 versus 17.9 months in the control versus experimental groups (hazard ratio, 0.40).

Personalized Cancer Vaccine Looks Promising in Early Study

By April 12, 2018

The researchers enrolled 25 platinum-pretreated, immunotherapy-naïve patients with recurrent advanced epithelial ovarian cancer (EOC) for the trial.

Rubraca Approved as Maintenance Treatment for Recurrent Ovarian Cancer

By April 06, 2018

The new approval was based on data from the Phase 3 ARIEL3 clinical trial (N=564).

Vigil Immunotherapy Tolerated Well for Recurrent Ovarian CA Tx

March 27, 2018

In the trial a personalized engineered autologous tumor cell vaccine was created incorporating rhGM-CSF DNA for enhanced antigen presentation and bifunctional shRNAfurin, which inhibits endogenous immunosuppression.

Genetic Assay of PAP Tests May Help Dx Endometrial, Ovarian CA

March 26, 2018

The researchers found that 81% of Pap brush samples from 382 endometrial cancer patients were positive, including 78% with early-stage disease. Among 245 ovarian cancer patients, sensitivity was 33%, including 34% with early-stage disease.

Metformin, Statin Use and Ovarian Cancer Risk: What's the Link?

February 27, 2018

The researchers found that 303 women were diagnosed with ovarian cancer during the follow-up period. Metformin was not associated with the incidence of ovarian cancer (hazard ratio, 1.02) compared to other oral antidiabetic medications.

USPSTF Issues Recommendation Statement on Ovarian Cancer Screening

February 13, 2018

Adequate evidence was also found suggesting that the harms of screening may be substantial in some cases, including unnecessary surgery in women without cancer. Based on these findings, the USPSTF concludes with moderate certainty that the harms of ovarian cancer screening outweigh the potential benefits.

Hyperthermic intraperitoneal chemotherapy with surgery increases survival for epithelial ovarian cancer patients

January 22, 2018

Patients with stage 3 epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) in addition to cytoreductive surgery and neoadjuvant chemotherapy experienced increased overall and recurrence-free survival.

Normal tissue BRCA1 methylation associated with risk for high-grade ovarian cancer

January 19, 2018

BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC).

Add-On Hyperthermic Intraperitoneal Chemotherapy Assessed in Ovarian CA

January 18, 2018

The researchers found that 89 and 81% of patients who underwent cytoreductive surgery without HIPEC and with HIPEC, respectively, had events of disease recurrence or death in the intention-to-treat analysis (hazard ratio, 0.66).

<i>BRCA1</i> Promoter Methylation and Ovarian CA Risk: Is There a Link?

January 16, 2018

Only patients with HGSOC had elevated methylation (9.6%; odds ratio, 2.91), in contrast to 5.1 and 4.0% of patients with non-serous ovarian cancer and low-grade serous ovarian cancer (LGSOC), respectively.

Levonorgestrel-Releasing IUD May Benefit in Early-Grade Endometrial Cancer

December 20, 2017

The researchers found that 15 of the 32 evaluable patients at the 6-month time point had complex atypical hyperplasia (47%), 9 had G1 endometrial cancer (28%), and 8 had grade 2 endometrial cancer (25%).

Can Co-Testing Support Longer Cervical Cancer Screening Intervals?

November 28, 2017

Regardless of the cytology result, 5-year ≥CIN3 risks for an HPV-negative co-test nearly matched the performance of a negative co-test for each successive round of screening (0.114, 0.061, and 0041%, respectively).

Opioid Rx Patterns Assessed Post-Hysterectomy

November 10, 2017

Patients reported using about half of the opioids prescribed, with a median excess of 110 oral morphine equivalents.

IUD Use and Cervical Cancer Risk: What's the Link?

By November 09, 2017

The data showed women who used IUD had a lower occurrence of cervical cancer (odds ratio [OR] 0.64, 95% CI: 0.53-0.77).

First Biosimilar For Cancer Treatment Approved

By September 14, 2017

The approval was based on evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data which demonstrated Mvasi is a biosimilar to Avastin.

USPSTF: Cervical Cancer Screening Recommendations Issued

September 13, 2017

For women aged 21 to 29 years, the USPSTF recommends screening for cervical cancer with cervical cytology alone every 3 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone or every 5 years with hrHPV testing alone (A recommendation).

Handheld Pen Device Rapidly Detects Cancerous Tissue

By September 08, 2017

Researchers at the University of Texas, who developed the MasSpec Pen device, tested its capability on 20 thin tissue sections (including breast tissues, thyroid tissues, papillary thyroid carcinoma, and follicular thyroid adenoma tissues) and 253 human patient tissue samples (including lung, ovary, thyroid and breast samples) some normal and some cancerous.

Many U.S. Women Think There's No Alternative to Hysterectomy for Fibroids

August 30, 2017

6% didn't first learn about it from their obstetrician-gynecologist; nearly three-quarters (73%) of women who knew about the treatment first heard about it from someone other than their obstetrician-gynecologist.

FDA Approves New Indication, Formulation for Lynparza

By August 18, 2017

The approvals were based on two, placebo-controlled trials (SOLO-2, Study 19) in patients with recurrent ovarian cancers who were in response to platinum-based therapy.

Cancer, CV Risks Examined for Vaginal Estrogen Tx in Postmenopausal Women

By August 16, 2017

The data showed women with an intact uterus did not have a significantly different risk of stroke, invasive breast cancer, colorectal cancer, endometrial cancer, and pulmonary embolism/deep vein thrombosis (PE/DVT) between those who used vaginal estrogen and those who did not.

Cancer Rates Assessed Post-Endometrial Ablation

August 14, 2017

Leiomyomas, age younger than 35 years, at least 2 prior cesarean deliveries, and history of sterilization were factors that predisposed patients to post-ablation hysterectomy.

USPSTF Issues Draft Recommendation Statement on Ovarian Cancer Screening

July 21, 2017

Test isn't accurate enough to justify its use, U.S. Preventive Services Task Force says

Study Examines ACA Impact on Early Cancer Detection

May 19, 2017

For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.

Amneal Introduces New Strength of Thiotepa with Tepadina

By April 27, 2017

Tepadina, an alkylating agent, is indicated to reduce the risk of graft rejection when used with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia.

Zejula Now Available for Recurrent Ovarian Cancer

By April 20, 2017

Zejula is the only PARP inhibitor that has demonstrated a clinically meaningful increase in progression-free survival in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status, in a randomized, prospectively designed Phase 3 clinical trial.

QoL Assessed After One Year of Ovarian CA Treatment

March 31, 2017

At one year, the mean global QOL score was lower for the standard chemotherapy group versus the concurrent-maintenance group.